Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals

AIDS

Volumn 23, Issue 9, 2009, Pages 1176-1179

  Van Der Lugt, Jasper ^a,b,h   Gorowara, Meena ^a   Avihingsanon, Anchalee ^a   Burger, David ^c   Ananworanich, Jintanat ^a,d   Sringam, Kancharat ^a   Kerr, Stephen ^a,e   Wit, Ferdinand ^b,f   Lange, Joep ^a,b,f   Ruxrungtham, Kiat ^a,g  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b International Antiretroviral Trial Evaluation Centre   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d University of Hawaii (SEARCH)   (Thailand)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f Academic Medical Centre   (Thailand)

^g CHULALONGKORN UNIVERSITY   (Thailand)

^h THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

RITONAVIR; RITONAVIR PLUS SAQUINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR;

AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; THAILAND; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTI-HIV AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RITONAVIR; SAQUINAVIR;

EID: 67651085606     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32832b4461     Document Type: Article

References (13)

1. Motwani B, Khayr W. Pharmacoenhancement of protease inhibitors. Am J Ther 2006; 13:57-63.
2. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV medicine 2005; 6:421-425.
3. Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and Safety of Atazanavir, With or Without Ritona-vir, as Part of Once-Daily Highly Active Antiretroviral Therapy Regimens in Antiretroviral-Naive Patients. J Acquir Immune Defic Syndr 1999. 2007.
4. Kilby JM, Sfakianos G, Gizzi N, Siemon-Hryczyk P, Ehrensing E, Oo C, et al. Safety and pharmacokinetics of once-daily regimens of soft-gel capsule saquinavir plus minidose ritonavir in human immunodeficiency virus-negative adults. Antimicrob Agents Chemother 2000; 44:2672-2678.
5. Autar RS, Boffito M, Hassink E, Wit FW, Ananworanich J, Siangphoe U, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005; 56:908-913.
6. Ananworanich J, Hill A, Siangphoe U, Ruxrungtham K, Prasithsirikul W, Chetchotisakd P, et al. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleo-side reverse transcriptase inhibitors in treatment-naive Thai patients. Antivir Ther 2005; 10:761-767.
7. Boyd M, Mootsikapun P, Burger D, Chuenyam T, Ubolyam S, Mahanontharit A, et al. Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100mg twice daily in HIV-1-infected Thai patients. Antivir Ther 2005; 10:301-307.
8. Ananworanich J, Gayet-Ageron A, Ruxrungtham K, Chetchotisakd P, Prasithsirikul W, Kiertiburanakul S, et al. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008; 13:375-380.
9. Droste JA, Verweij-Van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversedphase high-performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
10. Droste JA, Aarnoutse RE, Koopmans PP, Hekster YA, Burger DM. Evaluation of antiretroviral drug measurements by an interlaboratory quality control program. J Acquir Immune Defic Syndr (1999) 2003; 32:287-291.
11. Kilby JM, Hill A, Buss N. The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects. HIV Med 2002; 3:97-104.
12. Marta Boffito SC-T, De Lorenzo F, Waters L, Fletcher C, Back D, Mandalia S, Pozniak A, McGregor J, Gazzard B. Plasma Exposure of 100 mg Once and Twice Daily Decreases HDL and CD36 Expression but Only Twice-daily Dosing Increases Triglycerides: Potential Effect of RTV on Cardiovascular Disease. 15th Conference Retroviruses of Opportunistic Infections. Boston 2008.
13. Autar RS, Ananworanich J, Apateerapong W, Sankote J, Hill A, Hirschel B, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HI V-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004; 54:785-790.